Objective To observe the effect of dapagliflozin on cardiac function in patients with heart failure after emergency percutaneous transluminal coronary intervention in acute ST segment elevation myocardial infarction.
Methods A total of 100 patients with acute myocardial infarction underwent emergency PCI were randomly divided into study group (52 cases) and control group (48 cases). The study group was given dapagliflozin on the basis of standardized treatment of myocardial infarction, and the control group was given conventional treatment of myocardial infarction. Cardiac ultrasound related indexesleft ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), plasma N-terminal brain natriuretic peptide (NT-proBNP) level, 6-minute walking test (6MWT) results. The incidence of adverse reactions and major cardiovascular adverse events (MACE) were compared between the two groups during follow-up.
Results After 6 months of treatment, LVESD, LVEDD and LVEDV in the two groups were significantly lower than before treatment, and LVEF was significantly higher than before treatment (P < 0.05); the LVESD, LVEDD and LVEDV of the study group were significantly lower than those of the control group, and LVEF was significantly higher than that of the control group (P < 0.05). The NT-proBNP in the two groups was significantly lower than before treatment, and was significantly lower in the study group than that in the control group (P < 0.05). The 6MWT distance of the study group was significantly longer than that of the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions and MACE between the two groups (P>0.05).
Conclusion Dapagliflozin can improve cardiac function in patients with heart failure after emergency PCI of acute ST segment elevation myocardial infarction.
DownLoad: